Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
Office of Science and Data Policy (SDP)
The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.
The Office of Science and Data Policy includes several components:
- Division of Science and Public Health Policy
- Division of Evidence, Evaluation and Data Policy
- Division of Strategic Planning
Topic Areas:
- HHS Data Council
- Regulatory Impact Analysis
- Strategic Planning
- Information Quality Guidelines
- Prevention and wellness
- Public health systems and functions
- Food safety and nutrition
- Drugs and devices
- Tobacco control and prevention
- Biomedical research and development
- Economic analysis
- Emergency preparedness, response, and recovery
- Data and statistical policy
- Health disparities and vulnerable populations
- Health information technology
- Microsimulation
- Privacy policy
Reports
Displaying 51 - 60 of 158. 10 per page. Page 6.
Advanced SearchResearch Brief
Drug Checking Programs in the United States and Internationally: Environmental Scan Summary
This environmental scan presents a review and synthesis of approaches and strategies adopted by drug checking programs and existing evidence on their effectiveness in changing drug use attitudes, behavior, and health outcomes. It includes studies of drug checking programs across a variety of settings in the United States and internationally.
Report
Guidelines for Regulatory Impact Analysis Supplement: Addressing International Effects
This report extends the brief discussion of addressing international effects contained in the Department of Health and Human Service Guidelines for Regulatory Impact Analysis (2016). The purpose of this supplement is to expand that discussion and provide more detailed information on conducting such assessments.
Related Products:
ASPE Issue Brief
Parents' Intentions to Vaccinate Children Ages 12-17 for COVID-19: Demographic Factors, Geographic Patterns, and Reasons for Hesitancy
As of September 13, 2021, three vaccines to prevent infection with SARS-CoV-2, the virus that causes COVID-19, are available in the United States. The Pfizer vaccine was granted full approval for use in individuals over the age of 16 by the U.S.
ASPE Issue Brief
Trends in Antimicrobial Drug Prescribing During the COVID-19 Pandemic
COVID-19 has impacted antimicrobial drug prescribing both directly, through COVID-19 treatment, and indirectly, through the reduced spread of illnesses for which antimicrobial drugs are commonly prescribed.
Report
Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy
President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), identifies a lack of competition as a key driver for problems across economic sectors.
ASPE Issue Brief
The Impact of the COVID-19 Pandemic on Major HHS Data Systems
The COVID-19 pandemic and policy responses, including stay-at-home orders and expanded use of telework, disrupted data collection for major HHS data systems. This brief identifies the impact of the pandemic on 29 HHS statistical surveys and administrative data systems widely used by policymakers and the public.
Report
Valuing COVID-19 Mortality and Morbidity Risk Reductions in U.S. Department of Health and Human Services Regulatory Impact Analyses
This report develops an approach for valuing COVID-19 mortality and morbidity risk reductions based on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. Valuing risk reductions associated with regulations or other policies that address the novel coronavirus disease 2019 (COVID-19) presents major challenges.
ASPE Issue Brief
Unvaccinated for COVID-19 but Willing: Demographic Factors, Geographic Patterns, and Changes Over Time
As of August 4, 2021, 70.1 percent of U.S. adults have received at least one dose of a COVID-19 vaccine. However, vaccine coverage varies dramatically across the country, with vaccine coverage being less than 40 percent in a third of U.S. counties. Despite a sufficient supply of COVID-19 vaccines, daily vaccinations have dwindled in recent months.
Report
Appendix D: Updating Value per Statistical Life (VSL) Estimates for Inflation and Changes in Real Income
The HHS Guidelines for Regulatory Impact Analysis (2016) discuss an approach to valuing mortality risk reductions, commonly referred to as the value per statistical life (VSL). This appendix provides background information on the VSL estimates, describes the process for updating these values, reports the estimates in 2020 dollars, and illustrates their application.